Company intelligence / Profile preview

CC-Pharming

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

CC-Pharming is a Chinese biotechnology company founded in 2017, specializing in plant molecular medicine technology research and product development. It utilizes proprietary tobacco and lettuce transient expression platforms within an indoor vertical farming system to produce recombinant proteins and biologics, including a bio-better rituximab for non-Hodgkin lymphoma and autoimmune diseases. The company also offers CRO/CMO services.

Therapeutic areas: OncologyImmunology
Modalities: Monoclonal antibodyRecombinant proteinBiologic
Industry: Biotech

Partnerships

iBio

Beyond the preview

Go deeper on CC-Pharming.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CC-Pharming.

Explore the full profile